|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
The use of vedolizumab as second-line therapy for steroid-refractory gastrointestinal acute graft-versus host disease in childrenтезисы доклада Тезисы
- Авторы: Bronin G., Zhuravel M., Lifshits A., Seregin G., Zhuravel E., Kurmanov B., Taishikhina I., Burtsev E., Kumirova E., Maschan M.
- Сборник: Abstracts from the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT): : Physicians – Poster Session
- Том: 57
- Тезисы
- Год издания: 2022
- Издательство: Springer Science + Business Media
- Местоположение издательства: United States
- Первая страница: 100
- Последняя страница: 416
- Номер статьи: Р176
- DOI: 10.1038/s41409-022-01798-0
- Аннотация: The gastrointestinal (GI) graft-versus host disease (GVHD) remains to be challenging and life-threatening complication of hematopoietic stem cell transplantation (HSCT) in children. Steroid based treatment of this condition remains a universal standard first-line therapy. Despite authorization of new agents for second-line therapy, steroid refractory GI GVHD awaits safer and more effective therapeutic approach.
- Добавил в систему: Кумирова Элла Вячеславовна